Sung Yong Oh
YOU?
Author Swipe
View article: Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma Open
Background Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-cell maturation anti…
View article: Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy Open
In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Ther…
View article: Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4) Open
These findings demonstrate the clinical benefit of nivolumab combined with chemotherapy (either SOX or CAPOX) for first-line treatment of gastric cancer/gastroesophageal junction cancer in Korean patients.
View article: 618 | SEQUENTIAL BTK INHIBITOR THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL‐WORLD OUTCOMES AND ATTRITION RATES—FINAL REPORT FROM THE ASIA‐PACIFIC REGISTRY
618 | SEQUENTIAL BTK INHIBITOR THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL‐WORLD OUTCOMES AND ATTRITION RATES—FINAL REPORT FROM THE ASIA‐PACIFIC REGISTRY Open
View article: 808 | PHASE 1b/2 STUDY OF MAPLIRPACEPT (PF‐07901801), TAFASITAMAB, AND LENALIDOMIDE IN TRANSPLANT‐INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PARTICIPANTS
808 | PHASE 1b/2 STUDY OF MAPLIRPACEPT (PF‐07901801), TAFASITAMAB, AND LENALIDOMIDE IN TRANSPLANT‐INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PARTICIPANTS Open
View article: Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
View article: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
View article: Comprehensive clinico‐genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm
Comprehensive clinico‐genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm Open
View article: Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second‐line treatment (EAGLES, Korean Cancer Study Group UN18‐06)
Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second‐line treatment (EAGLES, Korean Cancer Study Group UN18‐06) Open
Background In this single‐arm, multicenter, phase 2 trial, the authors evaluated the efficacy and safety of avelumab plus gemcitabine in patients with leiomyosarcoma (LMS) who failed on first‐line chemotherapy. Methods Patients with advanc…
View article: Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids
Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids Open
Background The physical dependence on prescription opioids among cancer survivors remains an under-investigated area, with a scarcity of well-designed prospective studies. Methods This single-arm, phase-2 clinical trial in Korea assessed t…
View article: Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study Open
Purpose This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients acros…
View article: Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study Open
Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failur…
View article: PP213 Three-year follow-up of the ATTRACTION-4 Korean subgroup analysis: First-line (1L) nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated, advanced, or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer
PP213 Three-year follow-up of the ATTRACTION-4 Korean subgroup analysis: First-line (1L) nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated, advanced, or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer Open
View article: 661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation Open
View article: 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC) Open
View article: 1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study
1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study Open
View article: 1930P phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
1930P phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06) Open
View article: Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation Open
Introduction Upfront autologous stem cell transplantation (ASCT) has been recommended for patients who are newly diagnosed with peripheral T-cell lymphoma (PTCL), and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an an…
View article: P1167: TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION
P1167: TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: In human B-cell tumors, c-Myc rearrangements involving 8q24 is a hallmark of Burkitt lymphoma and other high-grade B cell lymphomas (HGBCL). Several studies have shown that …
View article: S311: EFFICACY OF INTRAVENOUS IRON TREATMENT FOR CANCER PATIENT WITH ANEMIA, RANDOMIZED CONTROLLED STUDY
S311: EFFICACY OF INTRAVENOUS IRON TREATMENT FOR CANCER PATIENT WITH ANEMIA, RANDOMIZED CONTROLLED STUDY Open
Topic: 29. Iron metabolism, deficiency and overload Background: Cancer/Chemotherapy Induced Anemia(CIA) is one of common and serious cancer or chemotherapy related complications. Previous studies have demonstrated benefits of intravenous(I…
View article: P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Odronextamab is a CD20×CD3 bispecific antibody (Ab). In the Phase 1 ELM-1 study (NCT02290951), odronextamab demonstrated encouraging activity and a generally manageable safe…
View article: A randomized phase II trial of CHOP versus ICED and autologous stem cell transplantation in newly diagnosed T‐cell lymphoma
A randomized phase II trial of CHOP versus ICED and autologous stem cell transplantation in newly diagnosed T‐cell lymphoma Open
Purpose: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas, and their prognoses are still poor because of frequent relapses and the absence of optimal standard therapy. Cyclophosphamide, doxorubicin, vi…
View article: TREATMENT PATTERNS IN PATIENTS WITH MANTLE CELL LYMPHOMA: UPDATED REPORT OF THE ASIA‐PACIFIC MULTINATIONAL RETROSPECTIVE REGISTRY STUDY
TREATMENT PATTERNS IN PATIENTS WITH MANTLE CELL LYMPHOMA: UPDATED REPORT OF THE ASIA‐PACIFIC MULTINATIONAL RETROSPECTIVE REGISTRY STUDY Open
Introduction: We conducted a multinational, multicenter retrospective registry study to better define the treatment patterns and survival outcomes of newly diagnosed patients with mantle cell lymphoma (MCL) in the Asia-Pacific region. Meth…
View article: Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study
Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study Open
Introduction: Primary CNS lymphoma (PCNSL) is a rare subtype of extranodal lymphoma with a dismal prognosis. Treatment options for patients with relapsed or refractory disease are extremely limited. Based on previously documented single-ag…
View article: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2 Open
Introduction: Odronextamab is a CD20×CD3 bispecific antibody (Ab). In ELM-1 (Ph1, NCT02290951), odronextamab demonstrated encouraging activity and a generally manageable safety profile in patients (pts) with heavily pretreated DLBCL (Banne…
View article: PROSPECTIVE KOREAN MARGINAL ZONE LYMPHOMAS COHORT STUDY: INITIAL DATA ANALYSIS OF 407 CASES
PROSPECTIVE KOREAN MARGINAL ZONE LYMPHOMAS COHORT STUDY: INITIAL DATA ANALYSIS OF 407 CASES Open
Background: Marginal zone lymphoma (MZL) is a distinct subgroup of non-Hodgkin's lymphoma (NHL), which is typically characterized by an indolent clinical course and long survival duration. In Korea, MZL accounts for 21% of all B-cell lymph…
View article: OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT
OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: RESULTS FROM KOREAN MULTICENTER COHORT Open
Introduction: Hodgkin lymphoma (HL) is a rare disease especially in Asian known to have good prognosis. However, in elderly patients (pts), due to comorbidities and poorer tolerance to treatment, the survival rate is not as good as in youn…
View article: A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy Open
Purpose Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient d…
View article: Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea
Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea Open
Several guidelines classify autologous stem cell transplantation (ASCT) as a low to intermediate risk group for infection. In a nationwide population-based study, using the Korean Health Insurance Review and Assessment Service database, pa…
View article: Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors Open
Background: With the development of immunology, immune checkpoint inhibitors (ICIs) have been widely used in various cancer treatments. Although some patients can benefit from ICIs, other patients have no response to ICIs or suffer from hy…